Skip to main content

FDA Updates

FDA Updates

Padcev Receives Regular FDA Approval for Locally Advanced or Metastatic Urothelial Cancer

FDA Updates

FDA Alert: Pepaxto (Melphalan Flufenamide) Associated with Increased Risk of Death in Postmarketing Clinical Trial

Breast Cancer, FDA Updates

FDA Approves Margenza for Treatment of Metastatic HER2-Positive Breast Cancer

FDA Updates

Gavreto, RET Inhibitor, FDA Approved for Metastatic NSCLC with RET Fusions

Lung Cancer, FDA Updates

Zepzelca New Therapy Approved for Metastatic Small-Cell Lung Cancer

FDA Updates

Opdivo Approved for Advanced Esophageal Squamous-Cell Carcinoma

Lung Cancer, FDA Updates

FDA Approves Cyramza plus Tarceva for First-Line Treatment of Metastatic NSCLC with EGFR Mutation

Lung Cancer, FDA Updates

Opdivo plus Yervoy and Chemotherapy Approved as First-Line Therapy for Metastatic NSCLC, Regardless of PD-L1 Expression

Hepatocellular Carcinoma, FDA Updates

Tecentriq plus Avastin First Immunotherapy Regimen Approved for Metastatic Hepatocellular Carcinoma

Prostate Cancer, FDA Updates

Lynparza First Targeted Therapy Approved for Metastatic Prostate Cancer with HRR Mutation

1
2
3
4
5

Page 2 of 13
Results 11 - 20 of 123